SAF-189 is under clinical development by Fochon Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SAF-189’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAF-189 is under development for the treatment of ALK- positive cancers like non small cell lung cancer and lymphoma. It is administered through oral route in the form of capsule. The drug candidate acts by targeting the ALK Kinase and receptor tyrosine kinase c Ros oncogene 1 (ROS1).
Fochon Pharmaceutical overview
Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.
For a complete picture of SAF-189’s drug-specific PTSR and LoA scores, buy the report here.